Groopman, Jerome
August 1996
New Republic;8/12/96, Vol. 215 Issue 7, p14
Discusses the possible factors that may amount to a cure of AIDS as presented at the AIDS Conference in Vancouver, British Columbia in August 1996. Drugs that slow the rate at which the human immune deficiency virus replicates; Factors that could improve the health of AIDS patients; Areas of the body where the virus reproduces; List of strategic aims that are based on the success and limitations of triple drug therapy.


Related Articles

  • Growth hormone treatment of children with human immunodeficiency virus-associated growth failure. Pinto, Graziella; Blanche, St├ęphane; Thiriet, Ingrid; Souberbielle, Jean Claude; Goulet, Olivier; Brauner, Raja // European Journal of Pediatrics;2000, Vol. 159 Issue 12, p937 

    Evaluates the acceptability, tolerance and efficacy of a daily subcutaneous injection of growth hormone in children with HIV virus. Drug therapy used; Effect of enteral feeding; Reason for the decrease in plasma leptin.

  • Behind the Headlines: Is a cure for AIDS in sight? Baines, Emma // GP: General Practitioner;11/25/2005, p20 

    The article presents information on a case study related to AIDS. It discusses an incident when a person miraculously recovered from this disease. According to media reports a man who has miraculously recovered from HIV may hold the secret to curing AIDS. The papers said that 25-year-old Andrew...

  • Iopamidol-induced meningoencephalopathy in an HIV-seropositive patient. Stroup, Jeffrey S.; Stephens, Johnny A.; Baker, Damon L. // Baylor University Medical Center Proceedings;Jan2007, Vol. 20 Issue 1, p39 

    Central nervous system infectious and metabolic abnormalities are common in HIV-positive patients. Drug therapy, opportunistic infections, the clinical course of HIV disease itself, and very rarely lodinated radiographic contrast agents can all be linked to these abnormalities. The following...

  • HIV chemotherapy. Richman, Douglas D. // Nature;4/19/2001, Vol. 410 Issue 6831, p995 

    The use of chemotherapy to suppress replication of the human immunodeficiency virus (HIV) has transformed the face of AIDS in the developed world. Pronounced reductions in illness and death have been achieved and healthcare utilization has diminished. HIV therapy has also provided many new...

  • Raltegravir combination therapy effective in untreated adults with HIV.  // British Journal of Hospital Medicine (17508460);Nov2011, Vol. 72 Issue 11, p608 

    The article reports findings of an ongoing STARTMRK phase III study which revealed that integrase inhibitor raltegravir (Isentress) tablets used in combination therapy were effective in untreated adult HIV-1-infected patients as compared to efavirenz in combination therapy.

  • HIV drug adds lean body mass.  // Healthy Weight Journal;Jul/Aug97, Vol. 11 Issue 4, p74 

    Reports that Serostim, an injectable drug for HIV-wasting syndrome leading to muscle weakness and organ failure and contributing to death, has won accelerated approval from the Food and Drug Administration. Side effects.

  • Amprenavir. Reddy, Prabashni; Ross, Jack // Formulary;Jul99, Vol. 34 Issue 7, p567 

    Presents a review of available clinical information on amprenavir, the fifth protease inhibitor approved by the United States Food and Drug Administration for HIV-1 infection treatment. Pharmacology; Pharmacokinetics; Comparative profiles of protease inhibitors; Clinical trials; Adverse events;...

  • Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature.  // Journal of Medical Case Reports;2011, Vol. 5 Issue 1, p1 

    The article presents a case study of a 47-year-old, Caucasian woman who developed Buffalo Hump at the time of antiretroviral therapy which includes raltegravir and unboosted atazanavir for treating Human Immunodeficiency virus (HIV)-1 infection. It informs that the diagnosis revealed that the...

  • Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. Gulick, Roy M.; Mellors, John W.; Havlir, Diane; Eron, Joseph J.; Gonzalez, Charles; McMahon, Deborah; Jonas, Leslie; Meibohm, Anne; Holder, Daniel; Schleif, William A.; Condra, Jon H.; Emini, Emilio A.; Isaacs, Robin; Chodakewitz, Jeffrey A.; Richman, Douglas D.; Gulick, R M; Mellors, J W; Havlir, D; Eron, J J; Gonzalez, C // JAMA: Journal of the American Medical Association;7/1/98, Vol. 280 Issue 1, p35 

    Context: Combination antiretroviral therapy can markedly suppress human immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among patients.Objective: To compare the antiretroviral effect of a 3-drug regimen started simultaneously or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics